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434Prospective multicenter study with a 1-year analysis
of a new vascular graft used for early cannulation in
patients undergoing hemodialysis
Marc H. Glickman, MD,a Jason Burgess, MD,b David Cull, MD,c Prabir Roy-Chaudhury, MD, PhD,d and
Harry Schanzer, MD,e Norfolk, Va; Charlotte, NC; Greenville, SC; Cincinnati, Ohio; and New York, NY
Objective:More than 85% of patients with end-stage renal disease start dialysis through a tunneled dialysis catheter (TDC)
for long periods while their arteriovenous ﬁstula or vascular access graft (arteriovenous graft [AVG]) matures. Because
TDCs are associated with a high risk of complications, including death and infection, use of an AVG that can be can-
nulated safely immediately after implantation may reduce morbidity in these patients by allowing earlier TDC removal.
We report a prospective multicenter study of a new early-cannulation AVG (Gore ACUSEAL Vascular Graft; W. L. Gore
& Associates, Flagstaff, Ariz).
Methods: Patients requiring creation of a prosthetic vascular access for hemodialysis were enrolled between July 2010 and
February 2012 and observed for 12 months. Data were collected on the patients’ baseline characteristics; location, po-
sition, loss of patency, and revisions of prior AVGs; dialysis sessions using the AVG; and major adverse events related to
graft implantation or cannulation. Cumulative and primary unassisted graft patency rates were calculated. A subgroup
analysis compared outcomes in patients in whom the AVG was ﬁrst cannulated within 72 hours after implantation with
outcomes in patients in whom the initial cannulation was performed >21 days postoperatively.
Results: The population of this study was formed by 138 patients who received an ACUSEAL graft. During follow-up,
17 patients died and the AVG was abandoned in 27. The median value for follow-up was 360 days for all patients
(variance 15,387). The overall mean time to initial cannulation was 15 days, with 54 grafts (40%) ﬁrst cannulated within
72 hours after graft implantation and 33 grafts ﬁrst cannulated >21 days afterward. The reason for late cannulation in
some patients was dependent on the implanting surgeon’s decision and the surgeon’s personal experience with early
cannulating grafts. The 1-year overall cumulative patency rate was 79% (95% conﬁdence interval, 71%-85%); the primary
unassisted patency rate was 35% (95% conﬁdence interval, 27%-44%). Adverse events included 6 hematomas (two of which
were related to cannulation and occurred 107 and 169 days, respectively, after AVG implantation), 15 graft infections,
and 15 cases of steal syndrome requiring intervention. Patients in the early- and later-cannulation groups had similar
characteristics and no signiﬁcant differences in rates of cumulative or primary unassisted patency or adverse events.
Conclusions: This study demonstrated that the new, early-cannulation AVGgraft can be cannulated soon after implantation
without a signiﬁcant difference in patency and complication rates comparedwith rates associated with standard cannulation
of expanded polytetraﬂuoroethylene grafts in the literature. This new AVG may allow early removal or avoidance of TDC
use in patients undergoing hemodialysis, potentially reducing or eliminating the number of days of catheter-dependent
dialysis, but further studies will be needed to demonstrate this potential. (J Vasc Surg 2015;62:434-41.)In patients with end-stage renal disease (ESRD), the
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://dx.doi.org/10.1016/j.jvs.2015.03.020changed appreciably during the past decade. The percentage
of incident hemodialysis patients with a TDC ranges from
78% to 81%.1-3 Possible reasons for this continued high rate
of TDC use include a lack of early referral, the patient’s
noncompliance, and an inability to obtain appropriate, timely
surgical intervention. Efforts have been made to decrease the
use of TDCs in the United States, but the incidence rate re-
mains high. TDCs have been observed to be associated with
high rates of morbidity and mortality within the ﬁrst 90 days
of starting hemodialysis.4 Infection, a frequent adverse effect
of TDC use, is the second most common cause of death in
patients undergoing hemodialysis, after cardiac events.5,6
Therefore, introduction of an early-cannulation graft for he-
modialysis is an attractive alternative because it may reduce
TDC contact time or avoid TDCuse entirely, either of which
has the potential to decrease infections and, possibly, the
occurrence of central venous stenosis.
Most patients who require a permanent prosthetic
vascular access for hemodialysis are given an expanded pol-
ytetraﬂuoroethylene (ePTFE) graft. Early cannulation of
standard ePTFE grafts has been reported, but these devices
Fig 1. The vascular access graft used in the study (Gore
ACUSEAL Vascular Graft; W. L. Gore & Associates, Flagstaff,
Ariz) has inner and outer layers of expanded polytetraﬂuoro-
ethylene (ePTFE) separated by a layer of medical-grade elastomer.
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and hematoma formation are possible when they are can-
nulated within hours or days after implantation.7
In April 2013, a new, multilayer ePTFE arteriovenous
graft (AVG; Gore ACUSEAL Vascular Graft; W. L. Gore
& Associates, Flagstaff, Ariz) was cleared for marketing
by the U.S. Food and Drug Administration (FDA). The
FDA-accepted instructions for use for this device state
that it can be cannulated for hemodialysis within 24 hours
of implantation. Early results with this AVG in small,
single-center, early-cannulation series were encouraging
with respect to patency and complication rates.8,9 Tozzi’s
experience in Europe demonstrated good patency rates
and low complication rates with early cannulation of this
graft.9 The FDA clearance of the AVG was based on
some of the data from the FDA-authorized clinical study
reported here.
The principal purpose of our multicenter study was to
evaluate the safety and efﬁcacy of the new AVG when can-
nulated in the early postoperative period (#72 hours after
implantation). We therefore determined the 1-year cumu-
lative and primary unassisted patency rates for the AVG
in a cohort of patients undergoing hemodialysis and docu-
mented any adverse events related to cannulation or dial-
ysis. In addition, because the time to ﬁrst cannulation of
the graft was observed to vary considerably in our cohort,
we elected to assess whether early cannulation might
reduce the number of days of TDC-dependent dialysis by
comparing outcomes in patients in whom cannulation of
the AVG was ﬁrst performed early after implantation
(#72 hours) with outcomes in those in whom the initial
cannulation occurred at a time commonly used for stan-
dard hemodialysis grafts (>21 days).
METHODS
Patients. The study was approved by the Institutional
Review Board for each of the 10 study centers, and all
enrolled patients or their legally designated representative
provided written consent to their participation. Patients
with ESRD were considered for enrollment if they pre-
sented between July 29, 2010, and February 29, 2012;
were currently undergoing hemodialysis or expected to
begin hemodialysis within 30 days; were not considered
candidates for creation of an arteriovenous ﬁstula (AVF);
and were able to have the AVG placed in an upper extrem-
ity. This determination was made by the surgeon and based
on vein mapping at each institution.
Patients were excluded from the study if they had pre-
viously had more than two vascular accesses in the arm in
which the AVG was to be implanted or they had a known
or suspected systemic infection, a hypercoagulable or
bleeding disorder, or a sensitivity to heparin. Also excluded
were patients who were receiving maintenance immuno-
suppression therapy or extended-release dipyridamole
plus aspirin.
Graft. The AVG used in this study is a 6-mm by 40-
cm trilayer device (Fig 1). It has an inner layer of ePTFE
bonded with heparin (CBAS Heparin Surface, W. L. Gore& Associates), a middle elastomeric layer, and an outer
layer of ePTFE. The heparin is bound to the inner ePTFE
surface by means of an end-point covalent attachment that
allows it to remain bioactive for several months.10 The
middle layer of the graft is intended to act as a sealant,
possibly reducing blood loss and the time to hemostasis at
cannulation sites. The cost of this graft is around
$200 more than a standard heparin-bonded ePTFE graft.
Graft implantation and cannulation. The patients’
physicians made all decisions about preoperative assessment
of veins in the upper extremity, the site of AVG implanta-
tion, the time of ﬁrst cannulation of the AVG, the need for
intervention to maintain or to restore AVG patency and the
type of intervention performed, and the treatment of any
adverse events. Patients were scheduled to be examined
by their clinicians 1, 3, 6, and 12 months after graft implan-
tation. Routine scanning was not part of the protocol. Cli-
nicians examined the patient, looked at the wounds, and
listened to the bruit of the graft. In accordance with the in-
structions for use for the graft, staff members at hemodial-
ysis centers were encouraged to maintain pressure on
needle exit sites for 10 to 15 minutes to achieve hemostasis
after decannulation of grafts implanted <14 days earlier.
Data collection and deﬁnitions. Data included pa-
tients’ baseline characteristics (demographic information,
comorbid conditions, and vascular access history); location,
position, loss of patency, and revisions of the AVG; time of
ﬁrst AVG cannulation; and major adverse events related to
graft implantation or cannulation. Data were collected pro-
spectively at each study site by using a web-based data-
capture system. Data collection in the study ended on
February 12, 2013.
Patients were referred for evaluation for a possible
AVG thrombosis when neither a thrill nor a bruit was
detected. Cumulative patency was deﬁned as freedom
from complete loss of the access regardless of whether in-
terventions were done to restore or to maintain patency
or to manage hematoma, infection, or steal syndrome dur-
ing the 12-month study period. Primary unassisted patency
Table I. Patients’ baseline demographic characteristics,
comorbid conditions, and vascular access history (total
N ¼ 138)
Variable Valuea
Age, years, mean 6 SD (range) 63 6 14 (27-94)
Male/female 67 (49)/71 (551)
BMI, kg/m2, mean 6 SD (range) 30 6 8 (17-56)
Raceb
African American 76 (55)
White 49 (35)
Other 14 (10)
Diabetes mellitus 83 (60)
Hypertension 134 (97)
Cardiovascular disease 70 (51)
Cerebrovascular disease 38 (27)
Peripheral arterial disease 24 (17)
Current tobacco use 32 (23)
Previous hemodialysis 114 (83)
Time receiving dialysis, years,
mean 6 SD (range)
2 6 3 (0-19)
No. of previous permanent
vascular accesses
1 64 (46)
2 25 (18)
$3 2 (1)
AVF or AVG currently in use 7 (6)
TDC currently in use 101 (89)
No. of previous TDCs
1 40 (29)
2 12 (9)
$3 3 (2)
AVF, Arteriovenous ﬁstula; AVG, arteriovenous graft; BMI, body mass
index; SD, standard deviation; TDC, tunneled dialysis catheter.
aValues are number (%) of patients unless otherwise indicated.
bAs reported by patient.
Table II. Graft implantation and cannulation data
Variable Valuea
Graft location
Upper arm 103 (75)
Forearm 35 (25)
Graft position
Loop 69 (50)
Straight 68 (49)
Reverse J 1 (1)
Graft cannulated at least once 135 (98)
Time of ﬁrst graft cannulation
after implantation
#24 hours 30 (22)
#48 hours 48 (36)
#72 hours 54 (40)
#1 week 70 (52)
Time to ﬁrst graft cannulation, days,
mean 6 SD (range)
15 6 21 (0-116)
Time to third consecutive HD
through graft, days, mean 6 SD (range)b
21 6 21 (3-123)
HD, Hemodialysis session; SD, standard deviation.
aValues are number (%) of patients unless otherwise indicated.
bIn 134 patients.
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without thrombosis or an intervention during the
12-month period.
In accordance with the standard care of patients with a
TDC who are switching to hemodialysis through a perma-
nent access, the TDCs that were in place in our patients at
enrollment were assumed to be eligible for removal after
the third consecutive successful dialysis session through
the AVG.11,12 Thus, in the data analysis, the third consec-
utive cannulation was considered the marker for the end of
catheter-dependent dialysis, even though some TDCs may
have remained in place awaiting orders for or scheduling of
removal.
Post hoc subgroup analysis. An initial assessment of
our data showed that ﬁrst cannulation of the AVG
occurred over a wide range of times after implantation.
We therefore conducted a post hoc subgroup analysis to
compare basic characteristics and outcomes in the 54 pa-
tients in whom the AVG was ﬁrst cannulated within
72 hours after implantation and the 33 patients in
whom the initial cannulation occurred >21 days postoper-
atively. The times were chosen with reference to the 2006
Clinical Practice Guidelines for Vascular Access, which
state that AVGs generally should not be cannulated for at
least 2 weeks after placement and that, in most cases,AVGs should be placed 3 to 6 weeks before the expected
start of hemodialysis.13
Statistical analysis. Kaplan-Meier analysis was used to
prepare the patency curves. Comparisons between the
early-cannulation (#72 hours after graft implantation)
and the later-cannulation (>21 days) groups were done by
using least square means, Fisher exact, or log-rank testing.
A P value of < .05 was considered to represent a signiﬁcant
difference between groups. All statistical analyses used
SAS version 9.2 software (SAS Institute, Cary, NC).
Sample size of 138 subjects was determined to be necessary
to obtain a 90% power to statistical 6-month cumulative
patency rate >60% using a one-sided binomial exact test
and a type I error rate of 2.5%.
RESULTS
Patients. A total of 138 patients with ESRD under-
went implantation of the AVG during the study period.
Table I shows their baseline demographic characteristics,
comorbid conditions, and vascular access history. At
enrollment, almost 90% of the patients were undergoing
hemodialysis through a TDC. The AVG was the ﬁrst per-
manent access for 34% of the patient cohort. The locations
and positions of the implanted AVGs are shown in
Table II. No patients were lost to follow-up. Sixteen
implanting surgeons were involved with this study.
Implantation by site included Burgess (30), Glickman (24),
Shuman (20), Cull (19), Gable (14), Kinter (10), Hurwitz
(7), Morrissey (6), Greene (6), and Ross (2).
Seventeen of the 138 patients enrolled in the study
died within a year of AVG implantation. The causes of
death were cardiac disease or cardiopulmonary arrest
(n ¼ 8), renal failure (n ¼ 2), respiratory failure (n ¼ 2),
multiple-organ failure (n ¼ 1), sepsis (n ¼ 1), bacterial
Fig 2. Kaplan-Meier curve showing cumulative graft patency in
the whole cohort for up to 12 months after graft implantation.
Patients who attended their 12-month follow-up visit earlier than
365 days after implantation were considered to have completed the
study and were therefore censored from the 12-month number at
risk. The standard error does not exceed 8%.
Fig 3. Kaplan-Meier curve showing primary unassisted graft
patency in the whole cohort for up to 12 months after graft im-
plantation. Patients who attended their 12-month follow-up visit
earlier than 365 days after implantation were considered to have
completed the study and were therefore censored from the
12-month number at risk. The standard error does not exceed 8%.
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failure (n ¼ 1). None of the deaths were considered by the
patients’ clinicians to be related to either the AVG implan-
tation procedure or use of the AVG for dialysis. The 17 pa-
tients who died during follow-up were included in the
calculation of primary unassisted graft patency until their
death but were censored from the 1-year cumulative
patency assessment because they were not alive at the
1-year time period for follow-up. In 27 of the enrolled pa-
tients, the AVG was eventually abandoned. These patients
were included in the assessment of loss of cumulative
patency, but they were not otherwise followed up after
graft abandonment. Abandonment was determined at
each site and consisted of repeated thrombosis or infection.
Cannulation variables. Graft cannulation data are
shown in Table II. Three of the AVGs were never cannu-
lated because the patient died before cannulation could be
performed (n ¼ 1), the graft was removed during the im-
plantation procedure because of inadequate arterial inﬂow
(n ¼ 1), or the graft was abandoned before cannulation
because of repeated clotting during implantation (n ¼ 1).
The mean time to ﬁrst cannulation of the remaining
135 grafts was 15 days (range, 0-116 days); the median
time was 5 days. The mean time to the third consecutive
successful hemodialysis session using the graft was 21 days
(range, 3-123 days; median, 15 days).
Graft patency. During the follow-up period, 80 of the
138 patients had a total of 220 graft revisions or in-
terventions, primarily percutaneous transluminal angio-
plasty or thrombectomy. The majority of stenoses (62%)
developed at the venous anastomosis. On Kaplan-Meier
analysis, the cumulative graft patency rate at 1 year was
79% (95% conﬁdence interval [CI], 71%-85%; Fig 2). The
1-year primary unassisted patency rate was 35% (95% CI,
27%-44%; Fig 3). No pre-emptive angioplasties were per-
formed in this study; 67% of the thrombosed grafts weretreated by percutaneous methods and the remainder by
surgical intervention.
Adverse events. Major adverse events related to graft
implantation and cannulation, including those that
occurred in patients who subsequently died or had graft
abandonment during the follow-up period, are shown in
Table III. No patient had a pseudoaneurysm or seroma
formation. The two hematomas that were related to can-
nulation occurred 107 and 169 days, respectively, after
AVG implantation. One of the hematomas resolved
without treatment, whereas the other resolved after partial
graft revision and administration of amoxicillin. Of the two
procedure-related hematomas, one (at the incision site)
resolved during prophylactic antibiotic treatment; the other
required explantation of the AVG. Of the two disease-
related hematomas, one was caused by extravasation dur-
ing a percutaneous transluminal angioplasty procedure at
the venous anastomosis and resolved after insertion of a
stent graft. The other resolved after treatment with prot-
amine, a heparin-reversing agent.
None of the 15 graft infections (Table III) were
considered by the patients’ clinicians to be related to the
AVG itself. All 11 infections related to the cannulation pro-
cedure developed between 45 and 351 days after the AVG
was implanted. Seven of the infections were treated suc-
cessfully with either antibiotic therapy alone (n ¼ 3) or
both antibiotics and partial graft revision (n ¼ 4). In the
other four patients, the grafts were abandoned and
explanted. Two of the three procedure-related infections
occurred 8 days after implantation and resolved after anti-
biotic therapy. The third reported infection was discovered
20 days postoperatively during a revision for thrombosis.
The AVG was explanted and a histologic analysis was per-
formed, but no bacteria were detected on either culture or
Gram staining. One wound infection considered to be
related to the patient’s underlying ESRD was observed
Table III. Major adverse events related to graft
implantation or cannulation
Event
No. (%) of
patients or eventsa
Any hematoma 6 (4)
Hematoma related to cannulation 2 (1)
Hematoma related to implantation
procedure
2 (1)
Hematoma related to disease 2 (1)
Bleeding at incision or suture site 6 (4)
Any graft infection 15 (11)
Graft infection related to cannulation 11 (8)
Graft infection related to implantation
procedure
3 (2)
Graft infection related to ESRD 1 (1)
Steal syndrome requiring intervention 15 (11)
Pseudoaneurysm 0
Graft inﬁltration or seroma 0
ESRD, End-stage renal disease.
aTwo patients had both a hematoma and bleeding at the incision or suture
site. The 15 cases of infection occurred in 13 patients, with two patients
having two infections.
Fig 4. Kaplan-Meier curve showing cumulative graft patency for
up to 12 months in patients in whom the graft was ﬁrst cannulated
either #72 hours or >21 days after implantation. Patients who
attended their 12-month follow-up visit earlier than 365 days after
implantation were considered to have completed the study and
were therefore censored from the 12-month numbers at risk. The
difference between the groups was not signiﬁcant on log-rank
testing (P ¼ .70). The standard error does not exceed 8%.
Fig 5. Kaplan-Meier curve showing primary unassisted graft
patency for up to 12 months in patients in whom the graft was ﬁrst
cannulated either #72 hours or >21 days after implantation.
Patients who attended their 12-month follow-up visit earlier than
365 days after implantation were considered to have completed the
study and were therefore censored from the 12-month numbers at
risk. The difference between the groups was not signiﬁcant on
log-rank testing (P ¼ .60). The standard error does not exceed 8%.
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resolved after antibiotic treatment. Symptoms of steal syn-
drome developed in 20 patients, 15 (11%) of whom
required a surgical intervention. In 10 of the 15 patients,
the symptoms resolved after treatment. Another patient
underwent graft ligation, and the remaining four patients
continued to have mild symptoms during the follow-up
period.
Post hoc subgroup analysis. The analysis comparing
patients in whom the AVG was ﬁrst cannulated within
72 hours after implantation (n ¼ 54) and those in whom
the initial cannulation was >21 days postoperatively(n ¼ 33) found no signiﬁcant difference between the
groups in body mass index, race, comorbid conditions,
vascular access history, or AVG location or position. How-
ever, there were statistically signiﬁcant differences in the
two groups in regard to both gender and age. Patients in
the early-cannulation group were signiﬁcantly younger
than those in the later-cannulation group (mean age,
61 years [range, 30-88 years] vs 68 years [range,
43-94 years]; P < .0001). There was also a signiﬁcant
difference between the two groups with respect to gender;
57% of patients in the early-cannulation group but only
30% of those in the later-cannulation group were men
(P ¼ .016).
The cumulative graft patency rates at 1 year in the two
subgroups were similar (76% [95% CI, 62%-86%] in the
#72 hours group vs 77.5% [95% CI, 58%-89%] in the
>21 days group; P ¼ .70; Fig 4), as were the 1-year pri-
mary unassisted patency rates (30% [95% CI, 18%-43%]
vs 41% [95% CI, 24%-57%]; P ¼ .60; Fig 5). There was
also no signiﬁcant difference between the groups in
freedom from hematoma (90.5% in the #72 hours group
[95% CI, 76%-96%] vs 97% [95% CI, 80%-100%] in the
>21 days group; P ¼ .34) or freedom from graft infection
(93% [95% CI, 82%-98%] vs 94% [95% CI, 80%-99%];
P ¼ .33) during follow-up.
The mean time to the third consecutive successful dial-
ysis session using the AVG was signiﬁcantly shorter in pa-
tients in whom the AVG was ﬁrst cannulated within
72 hours after implantation compared with patients in
whom the initial cannulation occurred >21 days postopera-
tively (7 days vs 47 days; P < .0001). Thus, on average, pa-
tients in the early-cannulation group were eligible to
become catheter independent within a week of implantation
of the AVG, whereas those in the later-cannulation group
Fig 6. Chart demonstrating number of patients who had successful early cannulation and the potential for catheter
removal. CVC, Central venous catheter.
JOURNAL OF VASCULAR SURGERY
Volume 62, Number 2 Glickman et al 439could not have become catheter independent for almost
7 weeks. The potential for catheter removal is demonstrated
in Fig 6. This demonstrates the number of patients cannu-
lated within 72 hours, successfully for three straight dialysis
times, and the potential for early catheter removal.
DISCUSSION
Vascular access-related infection and sepsis remain ma-
jor causes of morbidity and mortality in patients undergo-
ing hemodialysis. Rates of hospitalization in such patients
have increased 43% since 1993 and appear to be associated
with their high incidence of catheter use.1 Patients who
have ever had a TDC in place are seven times more likely
to have had an infection than those who had only an
AVF or AVG.14 Shingarev et al15 reported that 45% of all
failures of TDCs were due to catheter-related bacteremia,
with 35% of patients having an infection at 3 months after
catheter insertion, 54% at 6 months, and 79% at 12 months.
Moreover, central vein thrombosis has been reported to
occur in 26% of patients with a history of TDC use.16
Ravani et al17 showed that patients undergoing hemodial-
ysis through a catheter had a higher risk of death, infection,
and cardiovascular events than patients who did not have
catheters and had functioning AVFs or AVGs. Avoidance
of catheter use or substantially reducing the number of
days of catheter-dependent dialysis seems to be paramount
if changes in positive outcomes in hemodialysis-dependent
patients are to occur. This ideal could be achieved by hav-
ing an AVG with such characteristics that would allow safe
cannulation early after implantation, thus avoiding the
need of a TDC. In 1986, Schanzer et al18 reported favor-
able results with a ﬁrst generation of a three-layer PTFE/
silicone graft. This graft did not get wide clinical usebecause of no FDA approval. Further, early cannulation
of AVGs to address this issue has had variable results and
is not widely accepted.19-21
Most infections in functioning grafts occur after punc-
ture for hemodialysis or reoperation.22 The national com-
bined local and systemic infection rates for permanent
accesses, as calculated by the Vascular Access 2006 Work
Group, range from 1% to 4% for primary AVFs and from
11% to 20% for grafts during their expected periods of
use.13 The infection rate in our study (11%; n ¼ 5) was
therefore equivalent to the low end of the range for grafts.
Moreover, because the earliest cannulation-related infec-
tion occurred 45 days after AVG implantation, neither of
the two cannulation-related infections in our study could
have resulted from early cannulation.
Several risk factors for steal have been identiﬁed,
including diabetes, female sex, and brachial artery anasto-
moses.23,24 Symptoms of steal occur in 75% of patients
with an AVF and 90% of those with an AVG.25,26 The re-
ported rate at which steal in patients with a graft requires
intervention ranges from 5% to 15%.21,27,28 The rate in
our study was about 11%. This higher than expected rate
may have been related to the considerable proportion of
patients with diabetes in our cohort (60%). The ﬁndings
suggest that patients who are at high risk of steal may
beneﬁt from a more proximal arterial placement of the
AVG. Another possible cause of steal in our patients may
have been undetected proximal arterial stenoses, which
have been found to cause access dysfunction in >10% of
patients undergoing hemodialysis29 and to be present in
25% to 50% of those with access-related ischemia.30,31
Use of tapered grafts may reduce the occurrence of steal
in high-risk patients.32,33
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derwent cannulation within 72 hours after AVG implanta-
tion with those who had cannulation after the conventional
21-day period, there was no signiﬁcant difference between
the two groups in comorbid conditions, access history,
body mass index, race, hematoma formation, or infection
rate. Patients in the early-cannulation group were, howev-
er, signiﬁcantly more likely to be men and were signiﬁ-
cantly younger than those in the 21-day group. We do
not think that these differences affected outcomes because
neither gender nor age has been associated with improved
patency or a lower risk of complications in patients under-
going dialysis.
The time to the third consecutive dialysis session
through the AVG was signiﬁcantly shorter in the early-
cannulation group, indicating that earlier TDC removal
may be possible in patients given this graft, without an in-
crease in complications or a decrease in patency rate. Early
removal of TDCs may reduce septic complications in pa-
tients undergoing hemodialysis.
Our study had the usual limitations of a nonrandom-
ized investigation. However, we think that the results
indicate that early cannulation of the new AVG is safe
and feasible, that use of the device may allow a reduction
in TDC use, and that additional investigations of the
possible beneﬁts of early cannulation of the AVG are
warranted.
CONCLUSIONS
In a multicenter trial of the safety and efﬁcacy of a new
graft in 138 patients requiring a prosthetic vascular access
for hemodialysis, 30 patients underwent cannulation within
24 hours after graft implantation, 48 within 48 hours, and
54 within 72 hours. There were no differences in patency
or complication rates between patients in the early-
cannulation group (#72 hours) and those in whom the
AVG was ﬁrst cannulated 21 days after implantation. Use
of this AVG may provide patients with the opportunity
to reduce their number of days of catheter-dependent dial-
ysis or to avoid TDC use entirely, without a compromise in
safety.
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